一名金色短发、戴眼镜、身着西装、系着红色圆点领带的男子站在模糊的律师事务所背景前,体现了芝加哥律师的专业精神。

本杰明-R-戴丹

合作伙伴

Benjamin Dryden is an antitrust lawyer and serves as the vice chair of the Firm’s Antitrust & Competition Practice Group. His practice focuses on the antitrust issues that arise in mergers and acquisitions. His experience includes advising on the antitrust risk profiles of potential transactions, counseling clients through the due diligence and integration planning processes, negotiating antitrust risk provisions in purchase agreements, and representing clients in investigations before the Department of Justice, Federal Trade Commission, and state attorneys general. He has particular experience with transactions in the health care, technology, and manufacturing sectors. Benjamin also provides a broad range of antitrust counseling and compliance services, with focuses on the health care industry and in antitrust issues involving labor and employment.

In his M&A practice, Benjamin regularly represents clients in merger investigations before federal and state antitrust enforcers, including “Second Request” merger investigations. Because Second Requests can require sorting through massive volumes of documents in a short amount of time, Benjamin is an expert at leveraging artificial intelligence to achieve the best results in the quickest, most cost-effective way. In 2023, the legal technology company Relativity named Benjamin an “AI Visionary” for his innovative work deploying artificial intelligence in Second Requests.

In addition, Benjamin helps clients navigate the complex requirements of the Hart-Scott-Rodino (HSR) Act. He has prepared well over a hundred HSR filings and routinely advises clients on the intricate HSR reportability rules. He also negotiates and oversees “clean team” agreements to ensure compliant information-sharing throughout the due diligence and integration planning processes.

Benjamin provides a broad range of antitrust counseling services, including answering one-off counseling questions, providing employee trainings, and developing full-scale antitrust compliance programs. Benjamin complements his legal and industry knowledge with a down-to-earth, plain-spoken style, allowing him to effectively communicate complex concepts with a broad range of audiences. Benjamin is a sought-after speaker on antitrust topics, with quotes in publications such as the Wall Street Journal, CNBC.com, Reuters, National Law Journal, and Bloomberg Law, as well as scores of articles and presentations.

代表经验

  • Represented Matterport, Inc., the global leader in 3D digital twin technology, in its $1.7 billion sale to CoStar Group
  • Represented HonorHealth, a nonprofit health care system serving over five million people in the Phoenix and Scottsdale areas, in its acquisition of multiple health care facilities from Steward Health Care
  • Represented Quad/Graphics in its $1.4 proposed acquisition of LSC Communications, Inc.
  • Represented Mary’s Medical Center in merger with Cabell Huntington Hospital
  • Association of Equipment Manufacturers v. Burgum, 932 F.3d 727 (8th Cir. 2019), 2017 WL 8791104 (D.N.D. 2017) — Successful challenge to the North Dakota Farm Equipment Dealership Statute under the Contracts Clause of the United States Constitution.
  • Lloyd’s Material Supply Co. v. Regal Beloit Corp., 2017 WL 5172206 (C.D. Cal. 2017) — Achieved full dismissal of antitrust claims on grounds including lack of actionable conduct and lack of plausible antitrust injury.

奖项与表彰

  • Mondaq Thought Leadership Award for Antitrust/Competition Law (Fall 2024, Spring 2025)
  • Recipient, Washington Super Lawyers® Rising Stars list for Antitrust Litigation (2014-2023)
  • Artificial Intelligence Visionary, named by Relativity

Presentations and Media

  • Co-author, “Key Takeaways: 7th Annual “Let’s Talk Compliance,” Health Care Law Today (March 4, 2025)
  • Speaker, “Antitrust Issues in Provider Mergers & Acquisitions,” 7th Annual Let’s Talk Compliance Conference (January 24, 2025)
  • Speaker, “Federal and State Updates on Non-Compete Enforceability,” Foley & Lardner CLE Week (November 11, 2024)
  • Quoted, “Alaska-Hawaiian Merger, An Aviation Anomaly,” Law360 (September 30, 2024)
  • Quoted, “How the FTC’s noncompete ban could impact manufacturing operations and innovation,” Manufacturing Dive (May 8, 2024)
  • Panelist, “Takeaways from the Trenches: The JetBlue/Spirit Merger Trial,” ABA M&A Committee Program (May 3, 2024)
  • Quoted, “FTC Noncompete Ban Presents Several Trade-Offs For Behavioral Health,” Behavioral Health Business (April 24, 2024)
  • Quoted, “What We’ve Learned From Biden-Era Merger Remedies,” Law360 (April 22, 2024)
  • Quoted, “JetBlue-Spirit Ruling Casts Uncertainty Over Airline Deals,” Law360 (January 17, 2024)
  • Co-author, “Behind antitrust Enforcers’ 2023 Labor and Employment Push,” Law360 (December 19, 2023)
  • Quoted, “What the new health counsels at FTC, DOJ, and HHS might do,” STAT (December 19, 2023)
  • Co-author, “Biden Administration Announces New Efforts to Promote Competition in Health Care,” Health Care Law Today (December 8, 2023)
  • Quoted, “FTS-Amgen Deal: ‘Major Advance,’ Or ‘Narrow Assurance’?”, Law360 (September 7, 2023)
  • Co-author, “An Analysis of the “Deputization” Theory of Section 8 of the Clayton Act,” The Antitrust Source (August 2023)
  • Quoted, “2023 Is Far From Done With Government Merger Cases,” Law360 (July 20, 2023)
  • Quoted, “DOJ’s Merger Record Improves & Other Early 2023 Highlights,” Law360 (July 7, 2023)
  • Quoted, “What To Watch In Mass. Courts In The 2nd Half of 2023,” Law360 (July 3, 2023)
  • Quoted, ““FTC’s Proposed Rule to Ban Noncompetes Faces Stiff Resistance,” WorldatWork (May 31, 2023)
  • Co-presenter, “Recent Antitrust Developments in Health Care and Pharma” for the ABA Antitrust Law Section’s Health Care and Pharmaceuticals Committee (April 19, 2023)
  • Quoted, “Analysis: JetBlue faces ‘uphill battle’ in merger fight with government,” Reuters (March 9, 2023)
  • Speaker, “What the FTC’s Proposed Ban on Employee Noncompetes Means for Healthcare,” Association of Corporate Counsel, Health Law Network (March 7, 2023)
  • Co-presenter, “Prepare for 2023: What to Expect in Labor & Employment this Year,” Foley Insights (February 1, 2023)
  • Quoted, “Nonprofit hospitals may evade noncompete ban enforcement, experts say,” Healthcare Dive (January 20, 2023)
  • Quoted, “Proposed ban on noncompete clauses could affect ‘every business in the country,’ says attorney — what that means for you,” CNBC (January 11, 2023)
  • Quoted, “Kroger-Albertsons Antitrust Review Likely to Focus on Local Store Overlap,” The Wall Street Journal (October 21, 2022)
  • Quoted, “Labor Violations to Receive New Merger Scrutiny Via Agency Pact,” Bloomberg Law (July 22, 2022)
  • Quoted, “Mid-Year Update: No Antitrust Redux Yet Despite Stack of Bills,” Law360 (July 13, 2022)
  • Speaker, “Noncompetes under Attack – Biden Administration Seeks to Limit Restrictive Covenants in the United States,” Foley Insights (July 21, 2021)
  • Speaker, “A New Doctrine for Trust-Busting: The Evolving View on Antitrust Litigation” (June 2, 2021)
  • Speaker, “2021 Antitrust Trends in the US” (April 14, 2021)
  • Co-presenter, “Antitrust Counseling for Health Care Providers,” Foley Insights (October 22, 2020)
  • 联合主持人,美国律师协会反垄断法分会企业咨询委员会"反垄断动态"专题会议(2020年2月24日)
2025 年 10 月 29 日 新闻

本杰明-德赖登谈解决医疗机构竞业禁止问题的州级行动

Foley & Lardner LLP 合伙人 Benjamin Dryden 在 DukeHealth 的 "今日临床实践 "中介绍了各州对医疗雇主竞业禁止条款的监管方法。
石质建筑入口,门口上方刻有 "联邦贸易委员会 "字样。
2025 年 9 月 15 日 劳动与就业法视角

美国联邦贸易委员会决定放弃非竞争规则的五点启示

2025 年 9 月 5 日星期五,联邦贸易委员会(FTC 或委员会)结束了其多年来禁止员工竞业禁止协议的努力。请阅读 FTC 决定的五大要点。
2025年7月11日 福莱观点

司法部推出计划,以刑事罚款份额奖励反垄断举报人

2025年7月8日,美国司法部反垄断司("反垄断司")宣布推出一项新的"举报人奖励计划"...
2025 年 5 月 12 日 荣誉与奖励

富理达荣获《并购》杂志 "年度中间市场交易 "荣誉奖

Foley & Lardner LLP 为全球领先的全方位眼科药物和设备开发公司 Ora 在 2024 年由 The Vistria Group 进行的资本结构调整中提供咨询服务,因此获得了《并购》杂志 2025 年年度中间市场交易的荣誉奖。
在配备多台电脑显示器和控制面板的工作站前,操作员正通过键盘输入操作,为知识产权法律事务所提供诉讼支持服务。
2025年5月12日 福莱观点

规避算法定价软件反垄断风险的五大要点

近年来,无论是私人原告还是政府机构,都日益密切关注企业使用"算法定价"软件的情况,由此引发了一波反垄断诉讼和执法行动。
联邦贸易委员会大楼入口处设有装饰性金属大门,门上饰有船只图案,两侧配有壁灯,象征着知识产权法律背后的权威力量。
2025年4月14日 劳动与就业法视角

一年后,联邦贸易委员会的竞业禁止禁令仍处于维持生命状态,该机构正考虑终止该禁令

本博客读者或许还记得,去年四月,联邦贸易委员会沿党派路线投票通过了一项最终规则,该规则本将禁止全美绝大多数雇员竞业禁止协议。